Schedule of Information by Segment |
The
following table presents the significant segment expenses (10% or greater) and other segment items regularly reviewed by the Company’s
CODM and included in research and development costs for the three months and six months ended June 30, 2025 and 2024.
Schedule of Information by Segment
| |
2025 | | |
2024 | | |
2025 | | |
2024 | |
| |
Three Months Ended | | |
Six Months Ended | |
| |
June 30, | | |
June 30, | |
| |
2025 | | |
2024 | | |
2025 | | |
2024 | |
| |
| | |
| | |
| | |
| |
Clinical and related oversight costs | |
$ | 11,601 | | |
$ | 97,947 | | |
$ | 27,470 | | |
$ | 107,977 | |
Preclinical research focused on development of additional novel anti-cancer compounds | |
| 27,592 | | |
| 104,829 | | |
| 70,362 | | |
| 209,309 | |
Compound maintenance | |
| 20,265 | | |
| 5,976 | | |
| 53,083 | | |
| 9,870 | |
Regulatory service costs | |
| 1,190 | | |
| 1,956 | | |
| 1,190 | | |
| 2,616 | |
Total research and development costs | |
$ | 60,648 | | |
$ | 210,708 | | |
$ | 152,105 | | |
$ | 329,772 | |
The
following table presents a summary of research and development costs for the three months and six months ended June 30, 2025 and 2024
based on the respective geographical regions where such costs were incurred.
| |
2025 | | |
2024 | | |
2025 | | |
2024 | |
| |
Three Months Ended | | |
Six Months Ended | |
| |
June 30, | | |
June 30, | |
| |
2025 | | |
2024 | | |
2025 | | |
2024 | |
| |
| | |
| | |
| | |
| |
United States | |
$ | 41,928 | | |
$ | 114,345 | | |
$ | 100,499 | | |
$ | 148,928 | |
Spain | |
| 18,720 | | |
| 29,244 | | |
| 51,606 | | |
| 44,478 | |
China | |
| — | | |
| — | | |
| — | | |
| 2,282 | |
Netherlands | |
| — | | |
| 67,119 | | |
| — | | |
| 134,084 | |
Total research and development costs | |
$ | 60,648 | | |
$ | 210,708 | | |
$ | 152,105 | | |
$ | 329,772 | |
The
following table presents the significant segment expenses (10% or greater) and other segment items regularly reviewed by the Company’s
CODM and included in general and administrative costs for the three months and six months ended June 30, 2025 and 2024.
| |
2025 | | |
2024 | | |
2025 | | |
2024 | |
| |
Three Months Ended | | |
Six Months Ended | |
| |
June 30, | | |
June 30, | |
| |
2025 | | |
2024 | | |
2025 | | |
2024 | |
| |
| | |
| | |
| | |
| |
Compensation to related parties: | |
| | | |
| | | |
| | | |
| | |
Cash-based | |
$ | 123,285 | | |
$ | 175,663 | | |
$ | 232,016 | | |
$ | 390,398 | |
Stock-based | |
| 267,999 | | |
| 130,691 | | |
| 367,737 | | |
| 233,618 | |
Patent and licensing legal and filing fees and costs | |
| 17,303 | | |
| 63,612 | | |
| 73,386 | | |
| 146,823 | |
Other consulting and professional fees | |
| 176,551 | | |
| 191,529 | | |
| 381,867 | | |
| 363,972 | |
Insurance expense | |
| 64,277 | | |
| 126,873 | | |
| 128,553 | | |
| 253,727 | |
Other costs and expenses, net | |
| 64,746 | | |
| 110,080 | | |
| 146,085 | | |
| 257,725 | |
Total general and administrative costs | |
$ | 714,161 | | |
$ | 798,448 | | |
$ | 1,329,644 | | |
$ | 1,646,263 | |
The
following table presents the Company’s total assets by segment at June 30, 2025 and December 31, 2024.
| |
June 30, 2025 | | |
December 31, 2024 | |
| |
| | |
| |
Research and development assets | |
$ | 20,041 | | |
$ | 39,298 | |
Corporate assets (primarily cash) | |
| 1,168,537 | | |
| 1,106,205 | |
Total assets | |
$ | 1,188,578 | | |
$ | 1,145,503 | |
|